Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database
Open Access
- 10 March 2015
- Vol. 121 (13), 2230-2236
- https://doi.org/10.1002/cncr.29334
Abstract
BACKGROUND Waldenström macroglobulinemia (WM) is an indolent malignancy that predominantly affects older individuals who are at risk for secondary malignancies (SMs). The objective of this study was to characterize the incidence of SMs after a diagnosis of WM with the Surveillance, Epidemiology, and End Results (SEER) database. METHODS With SEER-13 data (1992-2011), standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) were calculated for the rates of solid and hematologic SMs in WM patients versus the general population. The analysis was stratified by age, sex, race, year of diagnosis, and latency from the WM diagnosis. RESULTS Among 4676 patients with WM, 681 SMs were recorded. The overall SIR was 1.49 (95% CI, 1.38-1.61), and the median time to an SM was 3.7 years. The cumulative incidence of SMs was 10% at 5 years and 16% at 10 years. The risk was significantly increased for cancers of the lungs, urinary tract, and thyroid; melanoma; aggressive lymphoma; and acute leukemia. The SIR for SMs in patients with WM was increased, regardless of age, sex, race, or year of diagnosis. CONCLUSIONS Patients with WM had a 49% higher risk of SMs than the general population. The selectively increased risk for hematologic SMs and certain solid SMs may be associated with transformation, therapy, and immune dysregulation. Cancer 2015;121:2230–2236. © 2015 American Cancer Society.Keywords
This publication has 28 references indexed in Scilit:
- Survival trends in Waldenström macroglobulinemia: an analysis of the Surveillance, Epidemiology and End Results databaseBlood, 2014
- Second malignancies among Waldenstrom macroglobulinemia patients: small samples and sparse dataAnnals of Oncology, 2011
- Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based studyBritish Journal of Cancer, 2011
- Risk of second cancers in Waldenström macroglobulinemiaAnnals of Oncology, 2011
- Associated Malignancies in Patients with Waldenström's Macroglobulinemia and Their KinClinical Lymphoma Myeloma and Leukemia, 2011
- Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma SubtypeJournal of Clinical Oncology, 2010
- InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directionsBlood, 2010
- Risk of second cancer after lymphohematopoietic neoplasmInternational Journal of Cancer, 2010
- Other Malignancies in Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJournal of Clinical Oncology, 2009
- Choice and Interpretation of Statistical Tests Used When Competing Risks Are PresentJournal of Clinical Oncology, 2008